CLINICAL OUTCOMES AND SPERM QUALITY AFTER CHEMOTHERAPY IN PATIENTS WITH TESTICULAR CANCER

Testicular cancer survival rates have increased to 95%, leading fatherhood becoming a major concern in half of male survivors. Since is not possible predict how chemotherapy (CT) will affect spermatogenesis, sperm cryopreservation before treatment highly recommended. It also unknown whether there an increase the rate chromosomal or epigenetic abnormalities post-CT sperm. Therefore, use fresh stored undergo IVF cycle decided on individual basis, based criteria attending doctor. Our aim was evaluate quality and clinical outcomes patients who had undergone CT be cured testicular cancer. This retrospective observational study including 119 diagnosed with attended our clinic between 1998-2019 cryopreserve semen undergoing CT. A new analysis performed 38 that return after their cure. The total concentration samples compared using paired t tests. Furthermore, results obtained by 27 were according origin (frozen vs. fresh) Fisher’s exact Tests. patient’s mean age at time 31.67 ± 6.20 years. spermiogram diagnosis moment was: normozoospermia (n=46, 38.65%), oligozoospermia (n=23, 19.33%), asthenozoospermia (n=13, 10.92%), oligoasthenozoospermia (n=26, 21.85%), cryptozooserpermia (n=5, 4.20%) azoospermia (n=6, 5.04%). After treatment, (31.93%) returned for second analysis. average interval elapsed 4.26 4.28 While 9 (23.68%) azoospermic 29 (76.32%) recovered spermatogenesis. Mean those 78.11 59.35 million, respectively (p>0.05). Twenty-seven underwent cycle. Following doctor's instructions, 20 used frozen pre-CT samples, while 7 samples. Comparable ongoing pregnancy (66.66% 56.75%; p>0.05), implantation (52.63% 43.39%; miscarriage (0% 14.28%; p>0.05) live birth (100% 90.47%; found respectively. Acording data, risk 24%. recover spermatogenesis count similar treatment. survivors obtain as good infertile population clinic, they sample